Bimekizumab well tolerated, efficacious over three years in axial spondyloarthritis. For patients with axial spondyloarthritis (axSpA), bimekizumab, a dual interleukin (IL)-17A and IL-17F inhibitor, is well tolerated over three years, according to a study published in the June issue of the Journal of Rheumatology.
A apuração publicada por medicalxpress.com vira base para uma leitura editorial direta e contextualizada.
Trechos de apoio da pauta: For patients with axial spondyloarthritis (axSpA), bimekizumab, a dual interleukin (IL)-17A and IL-17F inhibitor, is well tolerated over three years, according to a study published in the June issue of the Journal of Rheumatology.
- Ponto de atenção: bimekizumab.
- Ponto de atenção: well.
- Ponto de atenção: tolerated.
Em resumo, a leitura editorial acompanha o impacto do tema no nicho Fitness.
:quality(85)/a3030f3c-45cb-45f2-84a8-8b29673fabad.jpeg)